US2019290639A1PendingUtilityA1

Composition and method for treating skin conditions

57
Assignee: 442 VENTURES LLCPriority: Nov 4, 2010Filed: Jun 12, 2019Published: Sep 26, 2019
Est. expiryNov 4, 2030(~4.3 yrs left)· nominal 20-yr term from priority
Inventors:J. Mark Jackson
A61P 35/02A61P 35/00A61P 31/12A61P 43/00A61P 31/20A61P 1/02A61P 17/02A61P 17/00A61P 17/12A61P 15/00A61K 9/0019A61K 31/4745A61K 31/4436A61K 31/07A61K 31/203A61K 31/075A61K 31/60A61K 9/08A61K 45/06A61K 31/437A61K 31/455A61K 2300/00A61K 9/0014Y02A50/409Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition, comprising:
 imiquimod at a final concentration of between about 0.1% (wt/wt) and about 10% (wt/wt);   tazarotene at a final concentration of between about 0.001% (wt/wt) and about 1% (wt/wt); and   at least one additional ingredient selected from the group consisting of salicylic acid, urea, alpha-hydroxy acid, and beta-hydroxy acid at a final concentration of between about 0.5% (wt/wt) and about 70% (wt/wt).   
     
     
         2 . The composition of  claim 1 , wherein the ratio of the concentration of tazarotene to the concentration of imiquimod is less than 1:5. 
     
     
         3 . The composition of  claim 2 , wherein the ratio of the concentration of tazarotene to the concentration of imiquimod is less than 1:10. 
     
     
         4 . The composition of  claim 2 , wherein the imiquimod is at a final concentration of between about 0.1% (wt/wt) and about 8% (wt/wt). 
     
     
         5 . The composition of  claim 2 , wherein the imiquimod is at a final concentration of between about 0.1% (wt/wt) and less than about 8% (wt/wt). 
     
     
         6 . The composition of  claim 2 , wherein the tazarotene is at a final concentration of between about 0.001% (wt/wt) and about 0.1% (wt/wt). 
     
     
         7 . The composition of  claim 2 , wherein the tazarotene is at a final concentration of between about 0.001% (wt/wt) to less than about 0.1% (wt/wt). 
     
     
         8 . The composition of  claim 2 , wherein the tazarotene is at a final concentration of between about 0.001% (wt/wt) and about 0.01% (wt/wt). 
     
     
         9 . The composition of  claim 1 , wherein the at least one additional ingredient is salicylic acid. 
     
     
         10 . The composition of  claim 9 , wherein the salicylic acid increases penetration of the composition. 
     
     
         11 . The composition of  claim 10 , wherein the ratio of the concentration of tazarotene to the concentration of imiquimod is less than 1:10. 
     
     
         12 . The composition of  claim 1 , wherein the at least one additional ingredient is urea. 
     
     
         13 . The composition of  claim 12 , wherein the urea increases penetration of the composition. 
     
     
         14 . The composition of  claim 13 , wherein the ratio of the concentration of tazarotene to the concentration of imiquimod is less than 1:10. 
     
     
         15 . The composition of  claim 1 , wherein the at least one additional ingredient is alpha-hydroxy acid. 
     
     
         16 . The composition of  claim 15 , wherein the alpha-hydroxy acid increases penetration of the composition. 
     
     
         17 . The composition of  claim 16 , wherein the ratio of the concentration of tazarotene to the concentration of imiquimod is less than 1:10. 
     
     
         18 . The composition of  claim 1 , wherein the at least one additional ingredient is beta-hydroxy acid. 
     
     
         19 . The composition of  claim 18 , wherein the beta-hydroxy acid increases penetration of the composition. 
     
     
         20 . The composition of  claim 19 , wherein the ratio of the concentration of tazarotene to the concentration of imiquimod is less than 1:10.

Join the waitlist — get patent alerts

Track US2019290639A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.